BNP Paribas Financial Markets’s NovoCure NVCR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$7.72M Buy
708,293
+464,221
+190% +$5.8M ﹤0.01% 1717
2025
Q4
$3.16M Buy
244,072
+175,712
+257% +$2.26M ﹤0.01% 2332
2025
Q3
$883K Buy
68,360
+39,079
+133% +$522K ﹤0.01% 3206
2025
Q2
$521K Sell
29,281
-14,414
-33% -$251K ﹤0.01% 3300
2025
Q1
$779K Buy
43,695
+15,140
+53% +$344K ﹤0.01% 2942
2024
Q4
$851K Sell
28,555
-147,371
-84% -$3.12M ﹤0.01% 2929
2024
Q3
$2.75M Sell
175,926
-56,898
-24% -$1.03M ﹤0.01% 1870
2024
Q2
$3.99M Buy
232,824
+195,645
+526% +$3.44M ﹤0.01% 1530
2024
Q1
$581K Sell
37,179
-113,235
-75% -$1.67M ﹤0.01% 2767
2023
Q4
$2.25M Sell
150,414
-22,127
-13% -$296K ﹤0.01% 1884
2023
Q3
$2.79M Buy
172,541
+39,956
+30% +$1.15M ﹤0.01% 1662
2023
Q2
$5.5M Buy
132,585
+100,235
+310% +$6.22M 0.01% 1191
2023
Q1
$1.95M Buy
32,350
+4,871
+18% +$389K ﹤0.01% 1834
2022
Q4
$2.02M Sell
27,479
-8,912
-24% -$671K ﹤0.01% 1760
2022
Q3
$2.76M Sell
36,391
-67,580
-65% -$5.27M ﹤0.01% 1714
2022
Q2
$7.23M Buy
103,971
+39,373
+61% +$2.97M 0.01% 1062
2022
Q1
$5.35M Sell
64,598
-18,570
-22% -$1.37M 0.01% 1269
2021
Q4
$6.24M Buy
83,168
+56,584
+213% +$5.68M 0.01% 1219
2021
Q3
$3.09M Sell
26,584
-3,971
-13% -$600K ﹤0.01% 1609
2021
Q2
$6.78M Buy
30,555
+14,446
+90% +$2.81M 0.01% 1141
2021
Q1
$2.13M Sell
16,109
-7,741
-32% -$1.22M ﹤0.01% 1635
2020
Q4
$4.13M Buy
23,850
+18,111
+316% +$2.48M 0.01% 1242
2020
Q3
$639K Sell
5,739
-58,673
-91% -$4.69M ﹤0.01% 2068
2020
Q2
$3.82M Buy
64,412
+29,880
+87% +$1.97M 0.01% 1186
2020
Q1
$2.33M Buy
34,532
+1,960
+6% +$155K ﹤0.01% 1395
2019
Q4
$2.74M Buy
32,572
+16,916
+108% +$1.37M 0.01% 1524
2019
Q3
$1.17M Buy
15,656
+5,620
+56% +$449K ﹤0.01% 1773
2019
Q2
$635K Sell
10,036
-6,968
-41% -$353K ﹤0.01% 1899
2019
Q1
$819K Buy
17,004
+15,330
+916% +$738K ﹤0.01% 1802
2018
Q4
$56K Sell
1,674
-2,382
-59% -$87.1K ﹤0.01% 2659
2018
Q3
$213K Buy
4,056
+434
+12% +$17.3K ﹤0.01% 2376
2018
Q2
$113K Sell
3,622
-8,773
-71% -$244K ﹤0.01% 2727
2018
Q1
$270K Buy
12,395
+395
+3% +$8.5K ﹤0.01% 2621
2017
Q4
$242K Buy
12,000
+5,146
+75% +$99.1K ﹤0.01% 2868
2017
Q3
$136K Sell
6,854
-375
-5% -$7.37K ﹤0.01% 2634
2017
Q2
$125K Buy
7,229
+6,419
+792% +$82.9K ﹤0.01% 2715
2017
Q1
$6.56K Sell
810
-712
-47% -$5.14K ﹤0.01% 3256
2016
Q4
$11.9K Sell
1,522
-2,666
-64% -$21.4K ﹤0.01% 3376
2016
Q3
$35.8K Buy
4,188
+2,190
+110% +$20K ﹤0.01% 2584
2016
Q2
$23.3K Buy
1,998
+1,988
+19,880% +$24.9K ﹤0.01% 2530
2016
Q1
$145 Sell
10
-1,508
-99% -$21.6K ﹤0.01% 2611
2015
Q4
$33.9K Buy
+1,518
New +$36.3K ﹤0.01% 3063

Other funds holding NVCR

BNP Paribas Financial Markets's NVCR Position: Q1 2026 in Review

BNP Paribas Financial Markets increased its NovoCure (NVCR) stake by 190% in Q1 2026, buying an estimated $5.8M and bringing the position to 708,293 shares worth $7.72M. The position accounts for ﹤0.01% of the portfolio, ranked #1717.

BNP Paribas Financial Markets first reported a position in NVCR in Q4 2015 and has held it in 42 quarters since. 223 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

  • BNP Paribas Financial Markets held 708,293 shares of NovoCure worth $7.72M as of Q1 2026.
  • BNP Paribas Financial Markets bought 464,221 NovoCure shares in Q1 2026, an estimated $5.8M.
  • NovoCure made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #1717 holding.
  • BNP Paribas Financial Markets first reported a position in NovoCure in Q4 2015 and has held it in 42 quarters since.
  • 223 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.